A Phase I Multicenter Open-label First-in Human Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors
Brief description of study
This is a first-in-human modular Phase 1, open-label, multi-center study to evaluate the safety and tolerability and identify a recommended phase 2 dose (RP2D) of AZD9592 alone and with a specific combination treatment, in EGFR and cMET expressing tumors, initially NSCLC EGFR mut (L858R/ex19del) and wild type, as well as HNSCC. The study will also evaluate the preliminary efficacy, PK, PD and immunogenicity of AZD9592.
Clinical Study Identifier: s22-00831
ClinicalTrials.gov Identifier: NCT05647122
Principal Investigator:
Sally Lau.
Other Investigators:
Marta Wioleta Wronska,
Elaine Shum,
David Mendoza,
Nitish Mehta,
Vamsidhar Velcheti,
Kirby Rodriguez,
Shun Yu,
Danny Perlaza,
Laura Palazzolo,
Jessica Wang,
Jonathan B Kahn,
Joshua K Sabari,
Keriann M Scavone,
Marissa Rybstein,
Natalia Cherkassky,
Nina Beri,
Paul E. Oberstein,
Jagdeep Raince,
Elka R Travis,
Salman Rafi Punekar,
Carol M Lee,
Jeffrey G Schneider,
Jennifer Chuy,
Samantha VanMaanen,
Daniel J Becker,
Elise Roughan,
Kristen Spencer,
James Newman,
Gabrielle Fridman,
Melissa L Martinez,
Michael Shusterman,
Rafael Winograd,
Alexander A Hindenburg.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.